"Immunization, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
| Descriptor ID |
D007117
|
| MeSH Number(s) |
E02.095.465.425.400.485 E05.478.550.550
|
| Concept/Terms |
Immunization, Secondary- Immunization, Secondary
- Immunizations, Secondary
- Secondary Immunizations
- Immunization, Booster
- Booster Immunization
- Booster Immunizations
- Immunizations, Booster
- Secondary Immunization
|
Below are MeSH descriptors whose meaning is more general than "Immunization, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Immunization, Secondary".
This graph shows the total number of publications written about "Immunization, Secondary" by people in this website by year, and whether "Immunization, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 3 | 5 |
| 2017 | 0 | 4 | 4 |
| 2019 | 0 | 1 | 1 |
| 2022 | 1 | 2 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunization, Secondary" by people in Profiles.
-
Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2370087.
-
Receipt of COVID-19 Booster Dose Among Fully Vaccinated Pregnant Individuals Aged 18 to 49 Years by Key Demographics. JAMA. 2022 06 21; 327(23):2351-2354.
-
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
-
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
-
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Nov 04; 385(19):1774-1785.
-
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2021 01 07; 384(1):80-82.
-
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 11 12; 383(20):1920-1931.
-
Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods. Vaccine. 2019 07 26; 37(32):4460-4467.
-
Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals. Vaccine. 2018 02 01; 36(6):881-889.
-
Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine. J Infect Dis. 2017 12 12; 216(11):1343-1351.